Gene expression changes in mouse kidney cancer cells (RENCA) after anti-PD-L1 resistance
RNA-seq (gene expression) · mouse · 12 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Mus musculus (mouse)
- Samples
- 12 samples: 3 × RENCA Parental vs 3 × RENCA Parental met vs 3 × RENCA anti-PD-L1 Resistant vs 3 × RENCA anti-PD-L1 Resistant metGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Acquired resistance to PD-L1 inhibition enhances a type I IFN-regulated secretory program in tumorsEMBO reports · 2025
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE186037_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA772175 and SRA study SRP341881. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 12 samples.
How we read this: 4 replicated groups read from 12 sample titles; they account for 12 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM5629511 RENCA Parental rep 1 RENCA Parental
- GSM5629512 RENCA Parental rep 2 RENCA Parental
- GSM5629513 RENCA Parental rep 3 RENCA Parental
- GSM5629514 RENCA Parental met rep 1 RENCA Parental met
- GSM5629515 RENCA Parental met rep 2 RENCA Parental met
- GSM5629516 RENCA Parental met rep 3 RENCA Parental met
- GSM5629517 RENCA anti-PD-L1 Resistant rep 1 RENCA anti-PD-L1 Resist…
- GSM5629518 RENCA anti-PD-L1 Resistant rep 2 RENCA anti-PD-L1 Resist…
- GSM5629519 RENCA anti-PD-L1 Resistant rep 3 RENCA anti-PD-L1 Resist…
- GSM5629520 RENCA anti-PD-L1 Resistant met rep 1 RENCA anti-PD-L1 Resist…
- GSM5629521 RENCA anti-PD-L1 Resistant met rep 2 RENCA anti-PD-L1 Resist…
- GSM5629522 RENCA anti-PD-L1 Resistant met rep 3 RENCA anti-PD-L1 Resist…
- GSE275998 On the way to elucidate the effects of cannabidiol (CBD) on living organisms - assessment of changes in the global transcription profile of kidney in a mouse model 12 samples shares changes, kidney
- GSE278013 Cathepsin L as a dual-target to mitigate muscle wasting while enhancing anti-tumor efficacy of anti-PD-L1 [Bulk1] 14 samples shares anti-pd-l1
- GSE268774 Lymph node macrophages drive immune tolerance and resistance to cancer therapy by expression of the immune-regulatory cytokine IL-33 [RNA-seq] 48 samples shares resistance
- GSE218178 Adaptation to an acid microenvironment promotes pancreatic cancer organoid growth and drug resistance 183 samples shares resistance
- GSE281467 Coactivation of innate immune suppressive cells induces acquired resistance against cancer immunotherapy targeting the innate immune system [TIICs RNA-seq] 30 samples shares resistance
- GSE290828 Harnessing STING Signaling and Natural Killer Cells to overcome PARP Inhibitor Resistance in Homologous Recombination Repair altered Breast Cancer [RNA-seq] 20 samples shares resistance
- GSE275780 Dual Targeting of STING and PI3Kγ Eliminates Regulatory B Cells to Overcome STING Resistance for Pancreatic Cancer Immunotherapy [RNA-seq] 17 samples shares resistance
- GSE284264 Spatial genomics reveals cholesterol metabolism as a key factor in immunotherapy resistance in colorectal cancer [bulk RNA-seq] 16 samples shares resistance
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.